Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 4, 2021 (6 years ago)

Romidepsin Injecton

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Romidepsin Injecton, 27.5 mg/5.5 mL (5 mg/mL) Rx Only, 5.5 ml vial, Teva Pharmaceuticals USA, Inc. NDC 0703-4004-01

Affected NDC 0703-4004-01

Compare with the code on your package — it is the most precise check available.

Recalling firm
Teva Pharmaceuticals USA
NDC code
0703-4004-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0309-2021 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Teva Pharmaceuticals USA

All 2021 recalls

Other impurity / degradation recalls from 2021

All impurity / degradation recalls